Sangamo Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Sangamo Therapeutics, Inc. (SGMO)
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Sangamo Therapeutics, Inc. for potential securities fraud. This follows Pfizer's decision to return the development and commercialization rights for a hemophilia A gene therapy candidate, impacting Sangamo's prospects.
January 15, 2025 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics is under investigation for potential securities fraud after Pfizer returned rights for a key gene therapy candidate, raising concerns about Sangamo's future prospects.
The investigation into potential securities fraud and Pfizer's decision to return rights for a key therapy candidate are likely to negatively impact investor confidence and Sangamo's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100